Investor Relations
Investor Relations Contact:
LHA
Anne Marie Fields
212-838-3777
afields@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com

Media Contact
Rooney & Associates
Terry Rooney
212-223-0689
trooney@rooneyco.com
or
Marion Janic
212-223-4017
mjanic@rooneyco.com

OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder more »

OPKO Health's GeneDx to have Significant Presence at ACMG 2017 more »

OPKO Health to Participate in the Barclays Global Healthcare Conference more »

OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder¬† more »

SEC Filings

  
Filing Description Date Filed Sorted Descending Size View  
S-8 registration statement Sep 10, 1996 110.3 KB View HTML View PDF View XLS  
10-Q quarterly report Aug 14, 1996 66.0 KB View HTML View PDF View XLS  
SB-2/A amended registration statement for small business issuers Jul 25, 1996 631.1 KB View HTML View PDF View XLS  
10QSB quarterly report May 13, 1996 54.3 KB View HTML View PDF View XLS  
Showing 2,041-2,044 of 2044 Page: 1 ... 99 100 101 102 103  Previous 20

Email  Sign up for email alerts